Physician profile
Sherri Jackson
NPI 1235346495
$3,481.91
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $1,009 · 2021: $1,109 · 2022: $397 · 2023: $214 · 2024: $24.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $528.47 | 2019-2021 | |
| Novo Nordisk INC | $474.18 | 2019-2021 | |
| Abbvie INC. | $417.35 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.77 | 2019-2021 | |
| Glaxosmithkline, LLC. | $180.31 | 2020-2022 | |
| Amgen INC. | $176.02 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.76 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.65 | 2019-2022 | |
| Pfizer INC. | $113.47 | 2019-2022 | |
| Esperion Therapeutics, INC. | $102.57 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $97.28 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $95.09 | 2019-2021 | |
| Abbott Laboratories | $94.11 | 2019-2024 | Freestyle Libre 3 |
| Upsher-Smith Laboratories LLC | $79.41 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $69.01 | 2019-2023 | Farxiga |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $59.44 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $59.16 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $58.94 | 2021 | |
| Dexcom, INC. | $52.98 | 2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $47.05 | 2019 | |
| Lilly USA, LLC | $41.38 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $37.55 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $25.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.04 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.32 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.99 | 2021 | |
| Currax Pharmaceuticals LLC | $14.96 | 2021 | |
| Ironshore Pharmaceuticals INC. | $14.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.10 | 2021 | |
| Amneal Pharmaceuticals LLC | $12.09 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.58 | 2020 | |
| Shire North American Group INC | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherri Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.